Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
Comparative analysis suggested that Retatrutides unique triple agonist mechanism offered advantages over single or dual agonist approaches
As William Miller, CEO of Villya Pharmaceuticals and inventor of our patented technology (WO 2025/064695 A1), I appreciate the discussion around Lillys groundbreaking work in the GLP-1 space
Food and Drug Administration (FDA) has approved Ozempic (semaglutide) as the first and only GLP-1 receptor agonist (GLP-1 RA) specifically indicated to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD)
The long-acting strategies of GLP-1 drugs (amino acid substitutions, fatty acid side chain modifications, Fc fusion proteins, PEGylation) described in the article are only a small part of the current long-acting strategies, which have actually been applied to other protein-peptide drugs as early as
10.1016/j.jaci.2006.08.012
US$ 21.18
US$ 24.37
US$ 23.50
US$ 24.56
